STOCK TITAN

Autolus Therapeutics (NASDAQ: AUTL) CEO Itin reports Form 3 holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Autolus Therapeutics plc director and Chief Executive Officer Christian Itin filed an initial Form 3 reporting his equity holdings. He directly owns 1,116,009 Ordinary Shares and 50,000 American Depositary Shares, each currently representing one Ordinary Share.

He also holds multiple share options over American Depositary Shares with exercise prices between 1.46 and 30.29 per share and expirations from 2028 through 2036, plus 350,000 restricted share units that vest in four equal annual installments commencing on January 26, 2027.

Positive

  • None.

Negative

  • None.
Insider Itin Christian
Role Chief Executive Officer
Type Security Shares Price Value
holding American Depositary Shares -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Restricted Share Units -- -- --
holding Share Option (right to buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: American Depositary Shares — 50,000 shares (Direct); Share Option (right to buy) — 131,868 shares (Direct); Restricted Share Units — 350,000 shares (Direct); Ordinary Shares — 1,116,009 shares (Direct)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share. Fully vested and exercisable. This option vested 25% on July 22, 2023 and the remainder vested or vests in 36 equal monthly installments thereafter. This option vested 25% on March 6, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter. This option vested 25% on October 12, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter. This option vested 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Itin Christian

(Last)(First)(Middle)
C/O AUTOLUS THERAPEUTICS PLC
THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)
LONDONW12 7FP

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)1,116,009D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
American Depositary Shares (2) (2)Ordinary Shares50,000(2)D
Share Option (right to buy) (3)02/06/2028American Depositary Shares131,868$8.38D
Share Option (right to buy) (3)12/18/2028American Depositary Shares320,000$30.29D
Share Option (right to buy) (3)12/12/2029American Depositary Shares300,000$13D
Share Option (right to buy) (3)12/17/2031American Depositary Shares400,000$5.44D
Share Option (right to buy) (4)07/22/2032American Depositary Shares250,000$2.86D
Share Option (right to buy) (5)03/06/2033American Depositary Shares500,000$1.91D
Share Option (right to buy) (6)10/12/2033American Depositary Shares500,000$2.31D
Share Option (right to buy) (7)03/14/2035American Depositary Shares1,500,000$1.89D
Share Option (right to buy) (8)01/26/2036American Depositary Shares1,350,000$1.46D
Restricted Share Units (9) (9)American Depositary Shares350,000(10)D
Share Option (right to buy) (3)01/15/2031American Depositary Shares150,000$9.02D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one ordinary share.
2. Each American Depositary Share is convertible at any time at the option of the Reporting Person into one Ordinary Share.
3. Fully vested and exercisable.
4. This option vested 25% on July 22, 2023 and the remainder vested or vests in 36 equal monthly installments thereafter.
5. This option vested 25% on March 6, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter.
6. This option vested 25% on October 12, 2024 and the remainder vested or vests in 36 equal monthly installments thereafter.
7. This option vested 25% on March 14, 2026 and the remainder vests in 36 equal monthly installments thereafter.
8. This option vests 25% on January 26, 2027 and the remainder vests in 36 equal monthly installments thereafter.
9. The restricted share units ("RSUs") vest in four equal annual installments commencing on January 26, 2027.
10. Each RSU represents a contingent right to receive one Issuer American Depositary Share.
/s/ Christian Itin03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Autolus Therapeutics (AUTL) Form 3 filing show for CEO Christian Itin?

The Form 3 shows Christian Itin’s initial reported ownership in Autolus Therapeutics. He directly holds 1,116,009 Ordinary Shares, 50,000 American Depositary Shares, several share option awards over additional ADS, and 350,000 restricted share units that vest annually starting January 26, 2027.

How many Autolus Therapeutics (AUTL) Ordinary Shares does Christian Itin report on Form 3?

Christian Itin reports holding 1,116,009 Ordinary Shares of Autolus Therapeutics. In addition, the filing notes that each American Depositary Share currently represents one Ordinary Share, and he separately holds 50,000 American Depositary Shares on a direct ownership basis.

What derivative awards does Christian Itin hold in Autolus Therapeutics (AUTL)?

Christian Itin holds multiple share options over Autolus American Depositary Shares. These options have exercise prices ranging from 1.46 to 30.29 per share and expiration dates between 2028 and 2036, reflecting long-dated equity incentives tied to the company’s ADS.

What restricted share units (RSUs) are reported for Christian Itin in AUTL?

The filing reports 350,000 restricted share units for Christian Itin. These RSUs vest in four equal annual installments commencing on January 26, 2027, and each RSU represents a contingent right to receive one Autolus American Depositary Share upon vesting.

Are Christian Itin’s Autolus (AUTL) holdings direct or indirect in this Form 3?

All of Christian Itin’s reported holdings in this Form 3 are direct. The entries list ownership type and nature of ownership as direct, with no indication of indirect holdings through entities or trusts in the provided disclosure and footnotes.

Does the Autolus (AUTL) Form 3 show any recent insider buying or selling by Christian Itin?

The Form 3 functions as an initial ownership report rather than a trade report. The transactions are labeled as holdings with unknown transaction codes, and the transaction summary shows no buy, sell, or exercise activity in the data provided.